Coherus Oncology, Inc. (CHRS)

NasdaqGM • Currently unchanged in today's trading session

1 member of Congress has disclosed 2 trades in Coherus Oncology, Inc. (CHRS) via STOCK Act filings. The most recent disclosure was a sale by Shri Thanedar on 23 January 2023. Aggregate disclosed activity totals roughly $65K in sales (midpoint estimates from bracketed disclosure amounts).

Coherus Oncology, Inc. is currently trading at $1.43, positioned at 34% of its 52-week range ($0.81 – $2.62).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Copy PortfolioClaim Free Asset
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$1.43
24h Change
0.00 (0.00%)
52 Week Range
$0.81—$2.62
View on NASDAQ

Coherus Oncology, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for CHRS

Select to highlight on chart
1 transactions
Compliance: 50%
Shri Thanedar23 Jan 20239 Feb 2023SaleStock$15,001 - $50,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$175.05M

Volume

436.16K

Beta

0.98

P/E Ratio

-1.13

Fundamentals

EPS

$-1.26

Div. Yield

—

Open

$1.43

Day Range

$1.40 — $1.45

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Dennis Lanfear
IPO Date
2014-11-06
Website
www.coherus.com

Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies...

Earnings

Next Report

Q2 2026

6 Aug

EPS Est.

$-0.12

Rev. Est.

$14.4M

Days Until

14

Recent Quarters

Q1 202611 May
EPS$-0.25
Beat 5.1%
Q4 20259 Mar
EPS$-0.34
Beat 4.3%
Q3 20256 Nov
EPS$-0.33
Miss 3.1%
Q2 20257 Aug
EPS$-0.34
Miss 9.7%
Q1 202512 May
EPS$-0.35
Miss 12.9%
Q4 202410 Mar
EPS$-0.28
Miss 180.0%
Q3 20246 Nov
EPS$-0.01
Beat 90.0%
Q2 20248 Aug
EPS$-0.14
Beat 33.3%
Q1 20249 May
EPS$-0.32
Miss 540.0%
Q4 202313 Mar
EPS$-0.62
Miss 195.2%
Q3 20236 Nov
EPS$-0.27
Miss 28.6%
Q2 20232 Aug
EPS$-0.38
Beat 26.9%
Q1 20238 May
EPS$-0.75
Miss 22.9%
Q4 20226 Mar
EPS$-0.60
Beat 6.3%
Q3 20228 Nov
EPS$-0.96
Miss 81.1%
Q2 20224 Aug
EPS$-0.65
Beat 32.3%
Q1 20225 May
EPS$-1.24
Miss 55.0%
Q4 202117 Feb
EPS$-0.60
Beat 1.6%
Q3 20218 Nov
EPS$-0.49
Miss 22.5%
Q2 20215 Aug
EPS$-0.40
Miss 60.0%
Q1 20216 May
EPS$-2.37
Miss 2733.3%
Q4 202024 Feb
EPS$0.12
Miss 47.8%
Q3 20205 Nov
EPS$0.33
Miss 19.5%
Q2 20206 Aug
EPS$0.70
Beat 112.1%
Q1 20207 May
EPS$0.54
Miss 3.6%
Q4 201927 Feb
EPS$0.56
Miss 22.2%
Q3 20196 Nov
EPS$0.63
Beat 23.5%
Q2 20191 Aug
EPS$0.32
Beat 500.0%
Q1 20199 May
EPS$-0.29
Beat 37.0%
Q4 201828 Feb
EPS$-0.92
Miss 12.2%
Q3 20188 Nov
EPS$-0.87
Miss 10.1%
Q2 20188 Aug
EPS$-0.68
Beat 2.9%
Q1 201810 May
EPS$-0.74
Beat 3.9%
Q4 20178 Mar
EPS$-0.84
Miss 3.7%
Q3 20176 Nov
EPS$-1.09
Miss 3.8%
Q2 20177 Aug
EPS$-1.08
Beat 16.3%
Q1 20178 May
EPS$-1.54
Beat 0.0%
Q4 201613 Mar
EPS$-1.71
Miss 4.9%
Q3 20169 Nov
EPS$1.67
Beat 209.9%
Q2 20169 Aug
EPS$-1.72
Miss 17.0%
Q1 20169 May
EPS$-1.67
Miss 17.6%
Q4 201529 Feb
EPS$-1.35
Beat 22.4%
Q3 20159 Nov
EPS$-1.86
Q2 201510 Aug
EPS$-1.56
Q1 201511 May
EPS$-1.22
Q4 201423 Mar
EPS$-1.47
Miss 219.6%
Q3 201415 Dec
EPS$-0.25
Q3 201415 Dec
EPS$-1.79
Miss 108.1%
Q4 201331 Mar
EPS$-1.39
Q3 201331 Dec
EPS$-0.81
Q2 201330 Sept
EPS$-1.19
Q1 201330 Jun
EPS$-2.80
Q4 201231 Mar
EPS$-3.14

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about CHRS

Which members of Congress have traded CHRS?
1 member of Congress has disclosed 2 trade in Coherus Oncology, Inc. (CHRS) under the STOCK Act: Shri Thanedar.
When was CHRS most recently disclosed by Congress?
The most recent CHRS disclosure was a sale by Shri Thanedar on 23 January 2023.
What is the total disclosed congressional trading volume for CHRS?
Members of Congress have disclosed approximately $65K in CHRS sales (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in CHRS?
This CHRS page updates as soon as new STOCK Act disclosures are filed for Coherus Oncology, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
Follow on XJoin our Discord
PoliticiansBillsPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.